Search
for
Sort by
Research 511–540 of 1000+
- 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
- 46, XY 5-Alpha Reductase Deficiency in a 36-Year-Old Phenotypic Female Patient
- Change in hair growth-related gene expression profile in human isolated hair follicles induced by 5-alpha reductase inhibitors – dutasteride and finasteride – in the presence of testosterone
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- The efficacy of topical minoxidil 2% versus topical botanically derived inhibitors of 5 alpha reductase in treatment of female pattern hair loss by trichoscopy
- Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
- 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
- Pregnancy Outcomes with Paternal Exposure to Finasteride, a Synthetic 5-Alpha-Reductase Inhibitor: A Case Series
- Distribution of human B-defensin 2, TNF-alpha, IL-1 alpha, IL-6 and IL-8 in psoriatic skin
- Tumor necrosis factor-alpha inhibitor associated psoriasiform alopecia (drug-induced psoriasiform alopecia)
- After-rinsing hair growth promotion of minoxidil-containing amino alpha-cyclodextrins.
- 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
- 5-Alpha-reductase deficiency in a Saudi "girl"
- Finasteride prescribed for hair loss consistently leads to depression. Comment on ‘Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement’
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- BH02 Reversibility of 5-alpha reductase inhibitor effects on semen parameters: a review of human evidence
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- Evidence of Increased 3‐Alpha‐Androstanediol Glucuronide in Female Pattern Alopecia: A Cross‐Sectional Observational Study Evaluating Ovarian, Adrenal, and Peripheral Androgens
- Impact of 5-alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride.
- Intralesional methotrexate in patchy alopecia areata: trichoscopic evaluation and effect on lesional tumour necrosis factor alpha
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- An isotope dilution-liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of 5-alpha-dihydrotestosterone in human serum and plasma
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study